000			03208nam a22003975i 4500
999			_c367989 _d367989 _x1
001			367989
003			ES-MaUEC
005			20230102121656.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			220108s2022 sz | s |||| 0|eng d
020			_a9783030735722
024	7		_a10.1007/978-3-030-73572-2 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aR852 _b2022 EB
245	1	0	_aTumor Suppressor Par-4 : _bStructural Features, Molecular Mechanisms and Function _cedited by Vivek M. Rangnekar.
250			_aFirst edition 2022
264		1	_aCham _bSpringer International Publishing _c2022
300			_a1 recurso en línea (X, 323 páginas) _b84 ilustraciones, 81 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aarchivo de texto _bPDF
505	0		_aDiscovery and Overview of Par-4 -- Par-4 in cell cycle regulation -- Conformational studies of the Par-4 C-terminal Domain -- Structural analysis of Par-4 and crystallographic analysis of the regulatory domain -- Regulation of Par-4 by Ubiquitinases -- REGULATION OF PAR-4 FUNCTION BY PHOSPHORYLATION -- Role of Par-4 in GRP78 translocation -- PAR-4 in the regulation of stem cell death and embryo development -- RASSF2 and the PAR-4 connection -- Regulation of tumor suppressor Par-4 by ceramide -- PAWR as a direct SRC-1/HOXC11 suppression target -- Index.
520			_aPar-4 is a tumor suppressor protein first discovered and identified in 1993 by Dr. Vivek Rangnekar's laboratory in prostate cancer cells undergoing apoptosis. Par-4 (later also known as PAWR) is a naturally occurring tumor suppressor. Studies have indicated that Par-4 selectively induces apoptosis in cancer cells while leaving normal, healthy, cells unaffected. Mechanisms contributing to the cancer-selective action of Par-4 have been associated with protein kinase A activation of intracellular Par-4 in cancer cells or GRP78 expression primarily on the surface of cancer cells. Par-4 is downregulated, inactivated or mutated in diverse cancers. This first of two volumes will be the first on the market on the topic of Par-4, and will provide the opportunity for researchers to discuss the future direction of studies, broaden the scope of research, and contribute a more complete understanding of the molecule's structural features, key functional domains, regulation and relevant basic and clinical/translational facets.
988			_aSpringer_BiomedLife_2022
650		7	_2embne _9168783 _aMedicina _xInvestigación
700			_aRangnekar, Vivek M. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _9683003
776	0	8	_iPrinted edition: _z9783030735715
776	0	8	_iPrinted edition: _z9783030735739
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-73572-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE _n0
998			_b03/2022 _dz _ep _zSI